Serina Therapeutics Inc Dossier - Source-backed chat

Serina Therapeutics Inc

SERNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.39

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.95Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $49.5M

Enterprise Value $37.7M

Shares Outstanding 25.4M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Serina Therapeutics is a clinical-stage biotechnology company leveraging its proprietary poly(2-oxazoline) (POZ) polymer drug delivery platform to optimize therapeutics for neurological diseases. The company's lead candidate, SER-252 (POZ-apomorphine), is currently in a Phase 1b registrational study for advanced Parkinson's disease. Following a successful private placement (PIPE) in early 2026 that raised $21.2 million, Serina has significantly de-risked its balance sheet, extending its cash runway to support key clinical readouts. The POZ platform offers a non-immunogenic alternative to traditional PEG-lipid delivery systems, positioning Serina as an attractive candidate for both internal pipeline development and high-value out-licensing partnerships.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$9.50

High · most bullish analyst$11.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.2215%

SER-252 encounters clinical holds or safety concerns during dose escalation, stalling the Parkinson's program. The company fails to secure partnerships, leading to rapid cash burn, potential delisting from the NYSE American, and highly dilutive equity financing to sustain operations.

Base CaseCentral scenario

$11.0060%

Serina successfully completes Cohort 1 enrollment for SER-252 by Q3 2026 and delivers positive topline safety and pharmacokinetic data in H1 2027. The company maintains its NYSE American listing and selectively advances its follow-on candidate, SER-270, while securing early-stage research collaborations for its POZ-lipid LNP platform.

Bull CaseUpside scenario

$15.7525%

The Phase 1b trial of SER-252 demonstrates excellent safety and continuous dopaminergic stimulation, validating the POZ platform in humans. This triggers a major co-development or out-licensing partnership with a global pharmaceutical company, providing substantial non-dilutive funding and validating the platform for broader CNS and LNP-RNA applications.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary POZ Platform: Offers a synthetic, water-soluble, non-immunogenic alternative to PEG, avoiding anti-PEG antibody responses and enabling safer, long-acting drug delivery.
Lead Asset SER-252: Addresses a significant unmet need in advanced Parkinson's disease by providing continuous dopaminergic stimulation via a less invasive subcutaneous route.
Strengthened Balance Sheet: Early 2026 PIPE financing raised $21.2 million, boosting cash reserves to $24.5 million as of March 31, 2026, and eliminating debt obligations under the previous convertible note.

Key Investment Risks

Single-Asset Concentration: Valuation is heavily tied to the clinical success of SER-252, which is still in early-stage Phase 1b development.
Regulatory and Clinical Hurdles: Clinical trials are subject to delays, clinical holds, or failure to meet primary endpoints.
Listing Compliance: The company must execute its accepted compliance plan to maintain its listing on the NYSE American exchange.

Thesis Invalidation Triggers

Failure of SER-252 to demonstrate safety or continuous dopaminergic stimulation in the Phase 1b trial.
Inability to maintain NYSE American listing requirements, resulting in delisting to over-the-counter (OTC) markets.
Severe cash burn exceeding projections without securing non-dilutive partnership revenue or additional financing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.